

From: Chief Officer <chiefofficer@leics-lpc.co.uk>

Sent: 02 July 2026 15:31

Cc: ServiceDevelopmentLead <ServiceDevelopmentLead@leics-lpc.co.uk>

Subject: Please read** Inhaler Switch Programme (Fostair pMDI and generic beclometasone/formoterol pMDI to Luforbec pMDI)

Importance: High

FAO: ALL LLR Pharmacy Contractors and Teams

Sent on behalf: Medicines Optimisation Team Leicester, Leicestershire, and Rutland (LLR) ICB

We'd like to inform you of an upcoming formulary alignment programme planned for GP practices across Leicester, Leicestershire and Rutland (LLR) ICB in the next few months.

Information is being shared early to support community pharmacy contractors with planning, particularly around stock management, and to help maintain continuity of care for patients. This reflects our commitment to working collaboratively with community pharmacy.

The proposed change, in line with the LLR Formulary and APC guidelines, is:

Switching Fostair 100/6 and 200/6 pMDI (brand or generic) to the more cost-effective alternative, Luforbec pMDI.

While dry powder inhalers (DPIs) remain the preferred long-term option, the move from pMDIs to DPIs is gradual. In the meantime, switching patients from Fostair pMDI to Luforbec pMDI is appropriate and supports cost efficiency without affecting future DPI transitions.

Your continued support is appreciated.

Kind Regards
Rajshri Owen MRPharmS
Chief Officer